• Mashup Score: 2
    Webinar: Making Palliative Care a Part of Your Oncology Practice - 6 month(s) ago

    The 2023 ASCO President, Lynn Schuchter, MD, FASCO, has made providing palliative and supportive care to all patients with cancer a central focus in her presidential theme, “The Art and Science of

    Source: old-prod.asco.org
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of ASCO
      ASCO

      In recognition of World Hospice & Palliative Care Day, we’re pleased to present a new webinar that outlines practical tools for integrating palliative & supportive care into your oncology practice. Watch: https://t.co/Vp7oJUa5Jd @jrgralow @ASCOPres #WHPCDay23 #pallonc #supponc https://t.co/OZLOky7crc

  • Mashup Score: 2
    Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial - 7 month(s) ago

    PURPOSE Despite defined grades of 1 to 5 for adverse events (AEs) on the basis of Common Terminology Criteria for Adverse Events criteria, mild (G1) and moderate (G2) AEs are often not reported in phase III trials. This under-reporting may inhibit our ability to understand patient toxicity burden. We analyze the relationship between the grades of AEs experienced with patient side-effect bother and treatment discontinuation. METHODS We analyzed a phase III Eastern Cooperative Oncology Group-American College of Radiology Imaging Network trial with comprehensive AE data. The Likert response Functional Assessment of Cancer Therapy-GP5 item, “I am bothered by side effects of treatment” was used to define side-effect bother. Bayesian mixed models were used to assess the impact of G1 and G2 AE counts on patient side-effect bother and treatment discontinuation. AEs were further analyzed on the basis of symptomatology (symptomatic or asymptomatic). The results are given as odds ratios (ORs) and

    Source: ascopubs.org
    Categories: Latest Headlines, Oncologists1
    Tweet Tweets with this article
    • Profile photo of RyanNipp
      RyanNipp

      Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial. https://t.co/TcXX39ma6u @eaonc @ASCO @JCO_ASCO @JCOOP_ASCO #PallOnc #GeriOnc #SuppOnc #CancerResearch https://t.co/klbvLU8Q0N

  • Mashup Score: 2
    Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial - 7 month(s) ago

    Micro-AbstractIn patients with newly diagnosed lymphoma, low bone mineral density (BMD) is common at diagnosis and worsens with therapy. Our randomized phase III trial demonstrates that 2 doses of zoledronic acid (ZA) and supplementation with calcium and vitamin D effectively prevent further bone loss.

    Source: www.clinical-lymphoma-myeloma-leukemia.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of mtmdphd
      mtmdphd

      Zoledronic Acid for Prevention of Bone Loss in Lymphoma [12/29/12] @Lymphoma_Doc @mtmdphd et al. CLML https://t.co/iPOYSXEA1M #lymsm #SuppOnc #BoneHealth - Clinical Practice Points: 1) Incr risk low BMD in ND & incr risk on Tx, 2) 2 doses ZA stabilize BMD, 3) Screening

    • Profile photo of mtmdphd
      mtmdphd

      Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial [Dec 29, 2012] @Lymphoma_Doc @mtmdphd et al. CLML https://t.co/iPOYSXEA1M #NCT00352846 #lymsm #SuppOnc #BoneHealth https://t.co/ykQY5D5uy5

  • Mashup Score: 3
    Bone mineral density screening should be routine in lymphoma patients - 7 month(s) ago

    Drs Paccou et al. noted that ‘Adult patients with known lymphoma receiving chemotherapy experienced significant [bone mineral density] BMD loss at 1 year’ [1]. Their conclusions were drawn based upon 32 assessable patients with BMD better than -2.5 by T or Z scores. We find these data to be highly interesting as these results are similar to our randomized phase III clinical trial which evaluated the benefit of zoledronic acid (ZA) in the same lymphoma patient population [2]. In our trial, the patients who received ZA had stable BMD during the observation period.

    Source: www.annalsofoncology.org
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of mtmdphd
      mtmdphd

      BMD screening should be routine in lymphoma [2014] @mtmdphd @Lymphoma_Doc Hagemeister @Annals_Oncology https://t.co/USIjWZ7BOy #lymsm #SuppOnc #BoneHealth https://t.co/h9wflIUyKW

Load More